COMMUNIQUÉS West-GlobeNewswire

Tilray Brands Sets Sights on Asia: Bringing Award-Winning Craft Beers to Japan’s Premier American Craft Beer Experience Festival
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is [...]
Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor
30/10/2025
PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (“Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced that [...]
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
30/10/2025
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia’s trajectory towards [...]
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
30/10/2025
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five [...]
Roche purchases shares in tender offer for 89bio, Inc
30/10/2025
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly [...]
7 Stars, A New Glory of Yangtze in Global Quality Management
30/10/2025
TAIZHOU, China, Oct. 30, 2025 (GLOBE NEWSWIRE) -- On the evening of October 16 th (European Standard Time), at the EFQM Sustainable Performance Conference and Global Award Gala 2025 held in Spain, Yangtze River [...]
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
30/10/2025
The licensed small molecule program aims to address significant unmet needs for autoimmune diseases . Program adds to Boehringer’s pipeline and its commitment to deliver breakthrough therapies for patients with [...]
Inteleos Opens Africa Office to Advance Basic Obstetric Point of Care Ultrasound (OPOCUS) Certification Across East Africa
30/10/2025
Local Initiative Improves Access to Quality Maternal and Fetal Healthcare ROCKVILLE, Md. and NAIROBI, Kenya, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Inteleos, a global nonprofit healthcare certification organization, expands [...]
DBV Technologies participe au congrès scientifique annuel de l'ACAAI
30/10/2025
Châtillon, France, le 30 octobre 2025 DBV Technologies participe au congrès scientifique annuel de l'ACAAI DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT – CUSIP : 23306J309) une [...]
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
30/10/2025
Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), [...]
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
30/10/2025
Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in [...]
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
30/10/2025
This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007 (GalNAc-siRNA)” – “Next steps.” [...]
Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025
30/10/2025
BEIJING, Oct. 29, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest [...]
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
30/10/2025
ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”), a global, commercial stage, integrated [...]
Specialist Direct's ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes
30/10/2025
Strategic integration of advanced health engagement technology to enhance recovery journeys and promote healthier lifestyles Zurich, Switzerland, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Specialist Direct, a digital health [...]
Patients demand Ford government reimburse wrongful charges at Ford’s private clinics: more than 160 people join Day of Action at Ontario Legislature
29/10/2025
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Patients who have been wrongfully charged for surgeries and diagnostic tests at private clinics were joined by more than 160 supporters at the Ontario Legislature today for a “ [...]
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
29/10/2025
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned [...]
Veru Announces Proposed Public Offering
29/10/2025
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
29/10/2025
TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”) TX45 was well tolerated in patients with PH‑ [...]

Pages